Our latest Drug Safety Newsletter offers healthcare professionals essential information on safe and effective use of medicines. It includes information on:
→ Finasteride and Dutasteride: Outcome of EU review on risk of suicidal ideation
→ Bilastine (oral): New warning about risk of QT prolongation/Torsades de Pointes
→ Azathioprine: Updated hepatotoxicity warning
→ Mesalazine: New warning about idiopathic intracranial hypertension
Download the newsletter: https://t.co/1mWWhsyRhw
Our latest Drug Safety Newsletter provides healthcare professionals with information for using medicines safely and effectively.
This edition includes:
→ Updates on pregnancy outcomes with fluconazole and advice for women who could become pregnant
→ EU review begins on the link between suicidal thoughts and behaviours with finasteride and dutasteride
→ Higher risk of atrial fibrillation in patients with heart disease or risk factors when using Omega-3-acid ethyl esters
Download the newsletter: https://t.co/GKPiODLOLL
The IIOP are delighted to have collaborated with the NCCP on the creation of this important resource for pharmacists caring for patients with cancer
The Hub is now live on the IIOP website➡️https://t.co/4J5QC9n01E
#WorldPharmacistDay#CancerCareHub@hseNCCP@michelleodris
Our latest Drug Safety Newsletter offers valuable updates for healthcare professionals aimed at promoting the safe and effective use of medications.
This edition features articles on:
→ The inadvertent ocular exposure to chlorhexidine during surgical site preparation
→ The availability of educational materials for valproate and topiramate medicines
→ Highlighting the importance of reporting suspected adverse reactions
Download the newsletter: https://t.co/glTGtkdRO9
Check out our most recent NMIC Bulletin #NMICbulletin ‘Use of medicines with anticholinergic activity’, Vol 30, No.3 May 2024 at https://t.co/CENlrgzQxW
The May edition of the NMIC newsletter Therapeutics Today #NMICTT is now available athttps://nmiccomms.newsweaver.com/14ig36yfht/1x6fqz7xdhp. Check it out for information on risk of adverse events after initiation of AHT in older people; risk of serious falls and opioids.
Check out on most recent NMIC bulletin #NMICbulletin ‘Prostate Cancer Survivorship and Androgen Deprivation Therapy’ Vol 30, No.2. (April 2024) at
https://t.co/PA1T9QVn1p
Our latest Drug Safety Newsletter provides updates for healthcare professionals to support the safe and appropriate use of these medicines:
→ Valproate (Epilim): New precautionary measures for fathers taking the medicine in the three months before conception
→ NSAIDs: Updated recommendations on use during pregnancy
→ Cystic Fibrosis transmembrane conductance regulators: New warning on the risk of depression with specific medicines in this category
Download the newsletter: https://t.co/LMbG5EHQeH